FDA refuses investigator trials of PKAN drug; Retrophin hit
This article was originally published in Scrip
Shares of Retrophin plummeted almost 20% on 14 April after the company revealed the FDA is refusing to clear investigational new drug applications (INDs) for investigator-sponsored trials of RE-024, an phosphopantothenate replacement therapy, for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening neurological disorder.
You may also be interested in...
Fosmetpantotenate missed all endpoints in a Phase III trial, so Retrophin will shelve the candidate for the rare disease PKAN. Now, the biotech turns focus to Phase III sparsentan in a pair of indications.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.